



Boustead Singapore Limited
(Co. Reg. No. 197501036K)

67 Ubi Avenue 1, #02-01
StarHub Green
Singapore 408942

PROPOSED ACQUISITION OF 1% REDEEMABLE CONVERTIBLE NOTES OF BIO-TREAT TECHNOLOGY LIMITED

Singapore, 15 June 2010 – Mainboard-listed Boustead Singapore Limited (“Boustead” or the “Group”), a progressive global infrastructure-related engineering services and geo-spatial technology group today announced that its wholly-owned subsidiary, Boustead Knowledge Pte Ltd (“BK”) has entered into a sale and purchase agreement (the “SPA”) with Giant Delight Holdings Ltd (“GD”), a company incorporated in the British Virgin Islands, as vendor, and Chen Dawei, as guarantor for the performance by GD of warranties, undertakings, covenants, agreements and obligations contained in the SPA.

GD entered into a subscription agreement dated 11 December 2009 and a subsequent supplemental deed dated 29 April 2010 (collectively the “Subscription Agreement”) with Bio-Treat Technology Limited (“Bio-Treat”) pursuant to which Bio-Treat will be issuing HK\$290,084,400 (approximately S\$55,817,664) in aggregate principal amount of 1% redeemable convertible notes due within a maturity period of five years from the date of issue (the “Notes”) convertible into ordinary shares in the capital of Bio-Treat (the “Shares”) at the conversion price of S\$0.04 per Share. Upon completion under the Subscription Agreement, GD will be the legal and beneficial owner of the Notes.

Pursuant to the SPA, GD has agreed to sell to BK such part of the Notes as will be convertible into 854,180,330 Shares (the “Sale Notes”) for a consideration of S\$42,709,017 (the “Consideration”). Upon full conversion of all the Sale Notes, the 854,180,330 Shares to be issued by Bio-Treat to BK shall represent approximately 20.4% of the issued share capital of Bio-Treat on a fully-diluted basis, resulting in Bio-Treat becoming an associated company of Boustead. This represents an effective conversion price of S\$0.05 per Share for BK.

The Consideration was arrived at following arm’s length negotiations and on a willing-seller, willing-buyer basis and after taking into consideration, a) the five days average closing price of the Shares on the SGX-ST commencing 8 June 2010 and ending 14 June 2010 (both dates inclusive), b) the aggregate face value of the Sale Notes and the aggregate redemption value of the Sale Notes, and c) the prospects of Bio-Treat.

Should BK choose not to convert the Sale Notes, Bio-Treat and GD shall in aggregate repay to BK 110% of the Consideration on the date falling on the fifth anniversary of the date of issue of the Sale Notes (“Maturity Date”).

Under the terms of the SPA and pursuant to a Deed of Subordination to be entered into between GD and BK, a) the redemption of any Sale Notes held by BK will rank ahead of the redemption of any Notes held by GD; and b) all of Bio-Treat’s assets which were originally intended to be charged to GD pursuant to the issuance of the Notes and the Subscription Agreement will now be charged to BK.

BK's SPA with GD is also accompanied by a put option which will allow BK to require GD to purchase an equivalent and proportional combination of up to 50% of the outstanding Sales Notes and the Shares that have been converted and are held by BK.

Currently, Bio-Treat has an extensive portfolio of large-scale Built-Operate-Transfer and Transfer-Operate-Transfer projects in the People's Republic of China, including Beijing, Jiangsu, Shaanxi, Hubei and Shandong. Upon completion of these projects, Bio-Treat will have a daily treatment capacity of over one million metric tonnes of wastewater. According to press releases, Bio-Treat currently has treatment capacity of 955,000 metric tonnes a day and currently treats approximately 800,500 metric tonnes of wastewater a day.

The directors of Boustead are of the view that the acquisition is part of the Boustead Group's pursuit of strategic investments and the expansion of its investment portfolio. The business of Bio-Treat has been viewed as being complementary and synergistic to the Boustead Group's water and wastewater engineering division.

Save for Mr. Yeo Ker Kuang, a director of Boustead, who holds 1,000,000 Shares in Bio-Treat, none of the directors or controlling shareholders of Boustead has any interest, direct or indirect, in the acquisition.

The completion of the SPA is conditional upon a number of conditions being satisfied, including BK's satisfactory due diligence, as well as BK being able to negotiate and obtain certain warranties and covenants from Bio-Treat. There is no certainty that the SPA will be completed.

-- End of media release --

About Boustead Singapore Limited

Established in 1828, Boustead Singapore Limited is a progressive global Infrastructure-Related Engineering Services and Geo-Spatial Technology Group listed on the Singapore Exchange. Focusing on the engineering and development of key infrastructure supporting economic growth in the public and private sectors of emerging markets, our strong suite of Engineering Services comprises:

- Energy-Related Engineering;
 - Oil & Gas/Petrochemicals;
 - Solid Waste Energy Recovery;
- Water & Wastewater Engineering;
- Real Estate Solutions;
 - Industrial Real Estate Solutions; and
 - New Township.

Under our Geo-Spatial Technology arm, we provide professional services and exclusively distribute ESRI geo-spatial technology – the world’s leading geographic information systems and location intelligence solutions – to major markets across Australia and South East Asia. Our location intelligence solutions are essential to effectively plan, deploy and manage key infrastructure and resources in countries.

With a vast global network stretching across Asia, Australia, Europe, Africa and the Americas, Boustead is ready to serve the world. To date, Boustead has undertaken infrastructure-related projects in 79 countries globally.

In 2008 and 2009, Boustead was recognised in the prestigious Forbes Asia 200 Best Under A Billion as one of the Asia Pacific’s 200 best public-listed corporations under US\$1 billion in revenue. Boustead is also listed on the MSCI Global Small Cap Index for Singapore.

Visit us at www.boustead.sg.

Contact Information

For media and investor enquiries, please contact:

Mr Keith Chu
Vice President – Corporate Marketing & Investor Relations
Tel: +65 6747 0016 ext 112
DID: +65 6242 9362
Fax: +65 6741 8689
Email: keith.chu@boustead.sg